Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has signed an agreement with Epizyme for the discovery, development and commercialization of therapeutics targeting EZH2 as the treatment for lymphoma and other cancers.
Subscribe to our email newsletter
As per the terms of the agreement, Epizyme is entitled to get an upfront payment including research, development and sales milestones and royalties to Eisai as the project progresses.
Additionally, Eisai will fund 100% of R&D through human proof of concept, while Epizyme has the right to opt into a co-commercialization arrangement for the United States.
Eisai said that with this it seeks to make further contributions to addressing the diversified needs of and increasing the benefits provided to cancer patients and their families as well as healthcare professionals.